somewherepress
Has No Life - Lives on TB
/cloudfront-us-east-2.images.arcpublishing.com/reuters/ILJZNGVNLRPQ7BLVHAQCU7UW3I.jpg)
Ivermectin shows ‘antiviral effect’ against COVID, Japanese company says
Japanese trading and pharmaceuticals company Kowa Co Ltd on Monday said that anti-parasite drug ivermectin showed an "antiviral effect" against Omicron and other coronavirus variants in joint non-clinical research.
www.reuters.com
Japan's Kowa says ivermectin effective against Omicron in phase III trial
By Reuters Staff
1 MIN READ
TOKYO, Jan 31 (Reuters) - Japanese trading and pharmaceutical company Kowa Co Ltd said on Monday anti-parasite drug ivermectin has been found effective for treating the Omicron variant of COVID-19 in a Phase III trial.
The trial found ivermectin has “an antiviral effect” against the variant, Kowa said without providing further details. The firm has been working with Kitasato University, a medical university in Tokyo.
Clinical trials evaluating the drug, which is used to treat parasites in animals and humans, are ongoing but promotion of the drug as a COVID-19 treatment has generated controversy here.
The drug is not approved for treatment of COVID-19 in Japan and the U.S. Federal Drug Administration has repeatedly warned against its use.
Reporting by Sam Nussey and Rocky Swift; Editing by Tomasz Janowski
